Enhertu: Breast cancer treatment

The FDA-approved medicine Enhertu is a HER2-directed antibody-drug conjugate. The antibody is a humanized anti-HER2 IgG1. The small molecule, DXd, is a topoisomerase I inhibitor attached to the antibody by a cleavable linker. Enhertu is a sterile, white to yellowish-white, preservative-free lyophilized powder in single-dose vials in 100 mg to administer intravenously. The active ingredient in the medicine is Trastuzumab Deruxtecan with inactive ingredients L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and sucrose. The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology, and the topoisomerase inhibitor and linker are produced by chemical synthesis. Enhertu for injection is a white to yellowish-white lyophilized powder. The common side-effects of Enhertu are nausea, tiredness, vomiting, hair loss, constipation, decreased appetite, low red blood cell counts, low white blood cell counts, diarrhoea, cough, and low platelet counts.
The price of Enhertu is reasonable, and it is available among numerous wholesalers of Enhertu in India. For more details, please ring us on 18008891064.
Tweet